ALK and anaplastic large cell lymphoma: Whereas F1174C and F1174V are resistant to crizotinib and ceritinib in ALK+ NSCLC cell line models and patient samples [36, 47, 59], F1174V and F1174I are sensitive to both TKIs in ALK+ ALCL [39, 60].